Related Experiment Video
Updated: May 4, 2026
09:43
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
7.4K
Gliosarcoma: A rare primary CNS tumor. Presentation of two cases
José Pardo1, Mauricio Murcia1, Felip García2
1CAPIO-Hospital General de Catalunya, Radiation Oncology, Pedro i Pons n° 1, 08195 Sant Cugat del Vallès, Barcelona, Spain.
Summary
Gliosarcoma, a rare central nervous system tumor with glial and mesenchymal elements, presents diagnostic and histogenesis challenges. Understanding its biphasic nature is crucial for effective treatment strategies.
Area of Science:
- Neuro-oncology
- Pathology
- Central Nervous System Tumors
Background:
- Gliosarcoma is an exceptionally rare primary central nervous system tumor.
- It exhibits a distinctive biphasic pattern, combining glial and malignant mesenchymal components.
- Typically affects individuals between the fourth and sixth decades of life, with a male predominance (1.8:1 ratio).
Purpose of the Study:
- To present two distinct cases of gliosarcoma encountered and treated within our department.
- To highlight the diagnostic complexities and histogenetic uncertainties surrounding this rare tumor.
- To contribute to the understanding of gliosarcoma's unique biphasic nature.
Main Methods:
- Case report presentation of two gliosarcoma patients.
- Review of diagnostic findings and treatment modalities.
- Discussion of histopathological characteristics and origin.
Main Results:
- Two cases of gliosarcoma were successfully treated in the department.
- Standard treatment involved surgical resection, with adjuvant radiotherapy and chemotherapy in select instances.
- The biphasic nature of gliosarcoma was confirmed in both cases.
Conclusions:
- The precise monoclonal or biclonal origin of gliosarcoma's biphasic pattern remains an area of ongoing debate.
- Accurate diagnosis and understanding the histogenesis of gliosarcoma are critical.
- Further research is warranted to elucidate the origins and optimize treatment for this rare tumor.
